"Intermune, Inc; Pirfenidone Briefing Document" 9 March 2010 (2010-03-09), XP002580221 Retrieved from the Internet: URL:http://www.fda.gov/downloads/AdvisoryC ommittees/CommitteesMeetingMaterials/Drugs /Pulmonary-AllergyDrugsAdvisoryCommittee/U CM203083.pdf> [retrieved on 2010-04-29] (B1)

AZUMA ARATA ET AL: "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 1 MAY 2005 LNKD- PUBMED:15665326, vol. 171, no. 9, 1 May 2005 (2005-05-01), pages 1040-1047, ISSN: 1073-449X (B1)

LANDI M T ET AL: "Human cytochrome P4501A2." IARC SCIENTIFIC PUBLICATIONS 1999 LNKD- PUBMED:10493258, no. 148, 1999, pages 173-195, XP009132024 ISSN: 0300-5038 (B1)

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare: "Report on the Deliberation Results" 16 September 2008 (2008-09-16), XP009132612 Retrieved from the Internet: URL:http://www.pmda.go.jp/english/service/ pdf/Pirespa-Pirfenidone.pdf> [retrieved on 2010-04-22] (B1)

JEPPESEN U ET AL: "Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, vol. 51, no. 1, 1 January 1996 (1996-01-01), pages 73-78, XP009132566 ISSN: 0031-6970 (B1)

Banu A. Karimi-Shah, MD: "Clinical Review, NDA 22-535" 12 February 2010 (2010-02-12), XP002580220 Retrieved from the Internet: URL:http://www.fda.gov/downloads/AdvisoryC ommittees/CommitteesMeetingMaterials/Drugs /Pulmonary-AllergyDrugsAdvisoryCommittee/U CM203081.pdf> [retrieved on 2010-04-29] (B1)